Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,801 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Conventional Clear all
Not listed Not applicable Interventional

Serious Games for Parkinson's Disease

NCT05551338
View directory record Official record
Conditions
Parkinson Disease, Parkinson
Interventions
Serious games
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer

NCT00278148
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, Erlotinib, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Nathan Pennell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 21, 2026, 3:59 AM EDT
Not listed No phase listed Observational

Comparative Tobacco Interventions for Individuals With Severe and Persisting Behavioral Health Disorders

NCT04523948
View directory record Official record
Conditions
Tobacco Use
Interventions
Behavioral and pharmacological support to reduce combustible tobacco use.
Behavioral
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

NCT04301778
View directory record Official record
Conditions
Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Durvalumab, SNDX-6352
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Not applicable Interventional

Mindfulness Surgical Pain Outcomes

NCT05838443
View directory record Official record
Conditions
Post Surgical Pain, Surgery
Interventions
Self-directed mindfulness utilizing a multi-sensor EEG-supported device with neurofeedback-assisted and technology-supported meditation, Provider-directed mindfulness, Conventional Care
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 21, 2026, 3:59 AM EDT
Terminated Not applicable Interventional Results available

Flexitouch Treatment for Venous Ulcers

NCT00847002
View directory record Official record
Conditions
Venous Ulcer
Interventions
Standard Wound Care, Flexitouch System with Standard Wound Care
Device
Lead sponsor
Tactile Systems Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Minneapolis, Minnesota • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 21, 2026, 3:59 AM EDT
Active, not recruiting Not applicable Interventional

Project Looking-Glass Evaluation

NCT06056063
View directory record Official record
Conditions
Cone-Beam Computed Tomography
Interventions
Halcyon 4.0
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Phase 2 Interventional

Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment

NCT00680342
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Silymarin, Placebo
Drug · Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Not applicable Interventional

Next Science Wound Gel Efficacy in Chronic Wound Versus Standard of Care

NCT02138994
View directory record Official record
Conditions
Wound Chronic Draining
Interventions
Next Science Wound Gel, Triple Antibiotic Ointment Neosporin
Device · Drug
Lead sponsor
Next Science TM
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Phase 1 Interventional

Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00062322
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2010 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

NCT02013037
View directory record Official record
Conditions
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy, Heart Graft Dysfunction
Interventions
Eculizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 21, 2026, 3:59 AM EDT
Terminated Not applicable Interventional Results available

Hyperglycemia in Surgical Infections

NCT00353275
View directory record Official record
Conditions
Necrotizing Fasciitis
Interventions
Strict Glycemic control, Conventional Glycemic Control
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 21, 2026, 3:59 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

NCT03698019
View directory record Official record
Conditions
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
815
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Characterization of Nicotine Exposure and Urge-to-Smoke Following Use of Electronic and Conventional Cigarettes

NCT02210754
View directory record Official record
Conditions
Smoking
Interventions
blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle), blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle), blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle), blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle), blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle), Marlboro Cigarette
Other
Lead sponsor
Lorillard Tobacco Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 21, 2026, 3:59 AM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

NCT04801797
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Idarubicin, Daunorubicin, Liposomal daunorubicin and cytarabine, Venetoclax, Azacitidine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
9
States / cities
Duarte, California • Palo Alto, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma

NCT02661282
View directory record Official record
Conditions
Cytomegalovirus Positive, Glioblastoma, Gliosarcoma, Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
Interventions
Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis, Temozolomide, Therapeutic Conventional Surgery
Biological · Other · Drug + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 21, 2026, 3:59 AM EDT
Enrolling by invitation No phase listed Observational

Post Market Clinical Follow-Up Study for PROFEMUR® Preserve Classic Femoral Stem

NCT04147559
View directory record Official record
Conditions
Joint Diseases
Interventions
Total Hip Arthroplasty Implant
Device
Lead sponsor
MicroPort Orthopedics Inc.
Industry
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
2
States / cities
Scottsdale, Arizona • Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Results available

A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery

NCT01183559
View directory record Official record
Conditions
Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach
Interventions
Vandetanib, 5 Fluorouracil (FU), Carboplatin, Paclitaxel, External Beam Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Not applicable Interventional

mHealth Insulin Titration and Management (iSage)

NCT03704103
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
iSage
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

NCT02927769
View directory record Official record
Conditions
Hodgkin Disease
Interventions
Nivolumab, brentuximab vedotin, bendamustine
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 30 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Not applicable Interventional Results available

Brief Digital Intervention to Increase COVID-19 Vaccination Among Individuals With Anxiety or Depression

NCT06119854
View directory record Official record
Conditions
Misinformation, Vaccine Hesitancy, Anxiety, Depression, COVID-19
Interventions
Attitudinal inoculation, Cognitive-behavioral therapy-informed intervention, Conventional public health messaging
Behavioral
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
18 Years and older
Enrollment
1,419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Early Phase 1 Interventional

Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)

NCT03568994
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Atovaquone, Cytarabine, Daunorubicin, Etoposide, Gemtuzumab Ozogamicin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 20 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 21, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of Efficacy, Safety and Tolerability of Two Different 810 nm Diode Lasers for Hair Reduction

NCT01212172
View directory record Official record
Conditions
Hypertrichosis
Interventions
Soprano/SHR, LightSheer
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 21, 2026, 3:59 AM EDT
Active, not recruiting Not applicable Interventional

Robotic vs. Open NSM for Early Stage Breast Cancer

NCT05720039
View directory record Official record
Conditions
Breast Cancer Female, Breast Cancer, Breast Cancer, Early-Onset, Breast Disease, Breast
Interventions
Robotic NSM, Open NSM
Device · Procedure
Lead sponsor
Intuitive Surgical
Industry
Eligibility
21 Years and older · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
15
States / cities
Irvine, California • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 21, 2026, 3:59 AM EDT